Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report.

This technical report accompanies the American Academy of Pediatrics (AAP) policy statement (https://doi.org/10.1542/peds.2026-079047) and recommendations for respiratory syncytial virus (RSV) immunization during the 2026-2027 RSV season. The rationale is presented for recommending immunization of all infants younger than 8 months born during or entering their first RSV season, unless the infant has documented protection from vaccination of the pregnant parent; and infants and children 8 through 19 months of age who are at high risk of severe RSV disease and entering their second RSV season. The report synthesizes current evidence on RSV epidemiology, disease burden, immunization effectiveness, safety, and cost-effectiveness in pediatric populations; including evidence supporting expansion of high-risk groups for second season administration. Additionally, the report provides an overview of available RSV immunization products, formulations, and coadministration with other immunizations.